Preliminary Experience With Conversion From Calcineurin Inhibitors to Everolimus in Cardiac Transplantation Maintenance Therapy

Transplantation Proceedings

Volumn 40, Issue 9, 2008, Pages 3046-3048

  Sanchez Brotons J A ^a   Sobrino Marquez J M ^a   Lage Galle E ^a   Romero Rodriguez, N ^a   Guisado, A ^a   Jimenez Diaz J ^a   Benezet Mazuecos, J ^a   Arizon Munoz J M ^a   Mogollon M V ^a   Martinez A ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN; EVEROLIMUS; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; RAPAMYCIN; TACROLIMUS;

ADULT; ALLOGRAFT; ALLOGRAFT VASCULOPATHY; ARTICLE; CARDIAC GRAFT REJECTION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SUBSTITUTION; EDEMA; FEMALE; HEART TRANSPLANTATION; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; KIDNEY FAILURE; KIDNEY FUNCTION; MALE; PNEUMONIA; PRIORITY JOURNAL; VASCULAR DISEASE;

ADULT; AGED; CALCINEURIN; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; RETROSPECTIVE STUDIES; SIROLIMUS; T-LYMPHOCYTES;

EID: 55749100122     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2008.08.111     Document Type: Article

References (9)

1. Schuler W., Sedrani R., Cottens S., et al. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation 64 (1997) 36
2. Tereda N., Lucas J.J., Szepesi A., et al. Rapamycin blocks cell cycle progression of activated T cells prior to events characteristic of the middle to late G1 phase of the cycle. J Cell Physiol 154 (1993) 7
3. Augustine J.J., and Hricik D.E. Experience with everolimus. Transplant Proc 36 2 (2004) 500S
4. Tuzcu E., Kobashigawa J., Eisen H., et al. Favourable effect of everolimus on cardiac allograft vasculopathy is maintained through 24 months. J Heart Lung Transplant 23 (2004) S51
5. Eisen H., Tuzcu E., Dorent R., et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 349 (2003) 847
6. Majewski M., Korecka M., Joergensen J., et al. Inmunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from postransplant lymphoproliferative disorder at allograft-protecting doses. Transplantation 75 (2003) 1710
7. Starling R.C., Hareb J.M., Hauptmann P., et al. Therapeutic drug monitoring for everolimus in heart transplant recipients based on exposure effect modelling. Am J Transplant 4 (2004) 2126
8. Hummel M. Recommendations for use of Certican (everolimus) after heart transplantation: results from a German and Austrian Consensus Conference. J Heart Lung Transpl 24 4 (2005) 196
9. Kovarik J.M., Eisen H., Dorent R., et al. Everolimus in de novo cardiac transplantation: pharmacokinetics, therapeutic range, and influence on cyclosporine exposure. J Heart Lung Transpl 22 (2003) 1117